News
LPCN
2.070
+0.98%
0.020
Monday 10/5 Insider Buying Report: LPCN, CSWC
NASDAQ · 15h ago
Weekly Report: what happened at LPCN last week (0928-1002)?
Weekly Report · 23h ago
Insiders Pile Into Lipocine, Prothena, Pampa, AFC Gamma, ASP
TipRanks · 2d ago
Weekly Report: what happened at LPCN last week (0921-0925)?
Weekly Report · 09/28 09:52
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?
NASDAQ · 09/23 16:00
Lipocine Price Target Announced at $4.00/Share by HC Wainwright & Co.
Dow Jones · 09/21 16:46
HC Wainwright & Co. Reiterates Neutral on Lipocine, Announces $4 Price Target
Benzinga · 09/21 16:36
Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Lipocine (LPCN)
TipRanks · 09/21 16:10
H.C. Wainwright sets $4 price target on Lipocine
TipRanks · 09/21 16:00
Weekly Report: what happened at LPCN last week (0914-0918)?
Weekly Report · 09/21 09:53
Lipocine Highlights Strategy at Global Investor Conference
TipRanks · 09/16 20:58
Lipocine initiates Phase 3 study of LPCN 1154 for postpartum depression
TipRanks · 09/14 12:11
Lipocine Launches Phase 3 BLOOM Study for PPD
TipRanks · 09/14 10:48
Weekly Report: what happened at LPCN last week (0907-0911)?
Weekly Report · 09/14 09:56
Lipocine Updates Sales Agreement Fee Structure with A.G.P.
TipRanks · 09/11 10:29
Weekly Report: what happened at LPCN last week (0831-0904)?
Weekly Report · 09/07 09:51
Weekly Report: what happened at LPCN last week (0824-0828)?
Weekly Report · 08/31 09:56
Weekly Report: what happened at LPCN last week (0817-0821)?
Weekly Report · 08/24 09:57
Weekly Report: what happened at LPCN last week (0810-0814)?
Weekly Report · 08/17 09:58
Weekly Report: what happened at LPCN last week (0803-0807)?
Weekly Report · 08/10 09:54
More
Webull provides a variety of real-time LPCN stock news. You can receive the latest news about Lipocine Inc through multiple platforms. This information may help you make smarter investment decisions.
About LPCN
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.